Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer REDWOOD CITY, Calif., May 8, 2024 — Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the... May 8, 2024May 8, 2024
New Survey of U.S. Oncologists Reveals Where More Work Can Be Done to Research Treatments for Advanced Non-Small Cell Lung Cancer Survey examined oncologists’ perspective on treatment options and priorities, comorbidities and other clinical characteristics of patients with... January 24, 2024January 24, 2024
CRI CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey on Immunotherapy and Her Tenure NEW YORK – Jill O’Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute... December 21, 2023December 21, 2023
Cancer Research Institute Joins Lance Kawaguchi, #SouthPoleTrek4Cancer to Ring the Nasdaq Stock Market Closing Bell Contact: Melinda Koski, SouthPoleTrek4Cancer Sharon Slade, Chief Marketing Officer, CRI For Immediate Release Tuesday, December 19, 2023... December 19, 2023December 19, 2023
The Cancer Research Institute’s Patient Immunotherapy Summit is Now Available On Demand NEW YORK — The Cancer Research Institute (CRI) is excited to announce the premiere of the seventh... December 6, 2023December 6, 2023
CRI CEO Dr. Jill O’Donnell-Tormey on How Data Drives Immunotherapy Advances New York, November 22, 2023 Recently, the Cancer Research Institute’s (CRI) CEO and Director of Scientific Affairs... November 22, 2023November 22, 2023
